Results 11 to 20 of about 2,398,753 (259)

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production [PDF]

, 2023
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community.
Muneki, Isokawa, Sayaka, Kawaguchi, Tatsuya, Okuzumi, Yuri, Ooba, Rika, Takasugi, Yutaka, Matsuda, Natsuki, Shikida, Kazutaka, Shimbo, Tomohiro, Fujii, Tomohiro, Watanabe, Akira, Nakayama, Kei, Yamada, Takuya, Seki, Yusuke, Iwai, Noriko, Hatada, Brian. A., Mendelsohn, Kazutoshi, Takahashi   +16 more
core   +2 more sources

Supplementary Figure from Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen

, 2021
Supplementary Figure from Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible ...
Abhay K. Singh (15033101), Dennis E. Hallahan (10510788), Fong-Fu Hsu (256082), Dinesh Thotala (15033104), Vaishali Kapoor (15033107), Calvin D. Lewis (15033098)   +5 more
core   +4 more sources

Assembly of pH-Responsive Antibody-Inspired Protein-Drug Conjugates [PDF]

, 2021
With the advent of chemical strategies that allow the design of smart bioconjugates, peptide- and protein-drug conjugates are emerging as highly efficient therapeutics to overcome limitations of conventional treatment, as exemplified by antibody-drug ...
Seah Ling, Kuan, Michaela, Pieszka, Tao, Wang, Maksymilian Marek , Zegota, David Y. W. , Ng, Marco, Raabe, Tanja, Weil, Astrid , Heck, Lutz , Nuhn   +8 more
core   +2 more sources

Exploration of the antibody–drug conjugate clinical landscape

mAbs, 2023
The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 years. In November 2022, ElahereTM became the latest ADC to be approved by the US Food and
Heather Maecker, Vidya Jonnalagadda, Sunil Bhakta, Vasu Jammalamadaka, Jagath R. Junutula   +4 more
doaj   +1 more source

Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine. [PDF]

, 2012
BACKGROUND: A 9-valent pneumococcal conjugate vaccine (PCV-9), given in a 3-dose schedule, protected Gambian children against pneumococcal disease and reduced nasopharyngeal carriage of pneumococci of vaccine serotypes.
Greenwood, Brian M, Godwin C. Enwere, Brown J Okoko, Nsekpong, Ekpedeme D, Godwin C Enwere, Ekpedeme D Nsekpong, Syed M. A. Zaman, Aderonke A. Odutola, Saaka, Mark, Zaman, Syed MA, Akinsola, Adebayo K, Richard A. Adegbola, Syed M A Zaman, Adebayo K. Akinsola, Aderonke A Odutola, Richard A Adegbola, Martin O. C. Ota, Okoko, Brown J, Odutola, Aderonke A, Martin O C Ota, Cutts, Felicity T, Felicity T Cutts, Ekpedeme D. Nsekpong, Felicity T. Cutts, Adebayo K Akinsola, Brown J. Okoko, Enwere, Godwin C, Brian M Greenwood, Mark Saaka, Adegbola, Richard A, Brian M. Greenwood, Ota, Martin OC   +31 more
core   +1 more source

A disruptive clickable antibody design for the generation of antibody-drug conjugates

, 2023
298310Background: Antibody-drug conjugates are cancer therapeutics that combine specificity and toxicity. A highly cytotoxic drug is covalently attached to an antibody that directs it to cancer cells. The conjugation of the drug-linker to the antibody is
Miriam-Kousso Assi, Simon K Krebs, Stech, Marlitt, Rakotoarinoro, Nathanaël, Krebs, Simon, Nathanaël Rakotoarinoro, Yan F K Dyck, Maria K Parr, Dyck, Yan F.K., Parr, Maria K., Marlitt Stech, Assi, Miriam-Kousso   +11 more
core   +1 more source

Antibody drug conjugates

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +1 more source

"In vitro" and "in vivo" drug targeting using biotinylated immunoliposomes [PDF]

, 2005
The aim of my thesis was the optimization, characterization and application of a new, innovative drug carrier system which can be used to target pharmaceuticals to diseased tissues and organs.
Schnyder, Anita
core   +1 more source

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Haematologica, 2020
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, Francesca Guidetti, Giulio Sartori, Roberta Bordone, Alberto J. Arribas, Luciano Cascione, Mario Bigioni, Giuseppe Merlino, Alessio Fiascarelli, Alessandro Bressan, Afua Adjeiwaa Mensah, Gaetanina Golino, Renzo Lucchini, Elena Bernasconi, Davide Rossi, Emanuele Zucca, Georg Stussi, Anastasios Stathis, Robert S. Boyd, Rachel L. Dusek, Arnima Bisht, Nickolas Attanasio, Christian Rohlff, Andrea Pellacani, Monica Binaschi, Francesco Bertoni   +27 more
doaj   +1 more source

An Immunosuppressive Antibody–Drug Conjugate [PDF]

, 2015
We have developed a novel antibody–drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a humanized antibody that selectively binds with high affinity to CXCR4, an antigen that is ...
Travis S. Young (1610755), Chan Hyuk Kim (1322202), Stephanie A. Kazane (1480942), Wang, Ying, Lawson, Brian R, Rongsheng E. Wang (1628938), Deshmukh, Vishal, Schultz, Peter G, Brian R. Lawson (1639828), Cao, Yu, Peter G. Schultz (183240), Yu Cao (274482), Kim, Chan Hyuk, Tremblay, Matthew S, Tao Liu (10785), Jintang Du (1306560), Young, Travis S, Xiaozhou Luo (1628944), Du, Jintang, Matthew S. Tremblay (1480933), Wang, Feng, Luo, Xiaozhou, Kazane, Stephanie A, Feng Wang (44414), Vishal Deshmukh (1639831), Liu, Tao, Ying Wang (11406), Wang, Rongsheng E   +27 more
core   +1 more source